CIK 1931118
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 96.42% | 33 |
| Life Sciences Tools & Services | 3.13% | 1 |
| Unclassified | 0.45% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | SMMT | Summit Therapeutics Inc. | Health Care | 12.09% |
| 2 | IMVT | Immunovant, Inc. | Health Care | 6.35% |
| 3 | COGT | Cogent Biosciences, Inc. | Health Care | 6.19% |
| 4 | SVRA | Savara Inc | Health Care | 6.19% |
| 5 | URGN | UroGen Pharma Ltd. | Health Care | 4.98% |
| 6 | DFTX | Definium Therapeutics, Inc. | Health Care | 4.75% |
| 7 | VIR | Vir Biotechnology, Inc. | Health Care | 4.68% |
| 8 | PCVX | Vaxcyte, Inc. | Health Care | 4.59% |
| 9 | CLDX | Celldex Therapeutics, Inc. | Health Care | 4.08% |
| 10 | SION | Sionna Therapeutics, Inc. | Health Care | 4.04% |
34/35 names classified · sector 99.6% of weight · industry 99.6% · mkt cap 93.0%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 99.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 10% of book weight classified — the grid is NOT representative of the whole book.
Classified: 10.3% of book weight (4/35 names) · unclassified 89.7%: SMMT, IMVT, COGT, SVRA, URGN, DFTX, VIR, PCVX, CLDX, SION +21 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | SMMTSUMMIT THERAPEUTICS INC | 892,873 | $17M | 12.1% | NEW |
| 2 | IMVTIMMUNOVANT INC | 357,606 | $9M | 6.3% | ADD 24% |
| 3 | COGTCOGENT BIOSCIENCES INC | 225,158 | $9M | 6.2% | TRIM −39% |
| 4 | SVRASAVARA INC | 1,585,977 | $9M | 6.2% | ADD 59% |
| 5 | URGNUROGEN PHARMA LTD | 387,371 | $7M | 5.0% | TRIM −46% |
| 6 | DFTXDEFINIUM THERAPEUTICS INC COM SHS | 351,461 | $7M | 4.7% | NEW |
| 7 | VIRVIR BIOTECHNOLOGY INC | 730,548 | $7M | 4.7% | NEW |
| 8 | PCVXVAXCYTE INC | 110,454 | $6M | 4.6% | NEW |
| 9 | CLDXCELLDEX THERAPEUTICS INC NEW | 180,048 | $6M | 4.1% | ADD 104% |
| 10 | SIONSIONNA THERAPEUTICS INC | 141,024 | $6M | 4.0% | TRIM −22% |
| 11 | GMABGENMAB A/S | 196,709 | $5M | 3.8% | ADD 575% |
| 12 | ZLABZAI LAB LTD | 275,818 | $5M | 3.7% | ADD 40% |
| 13 | VRTXVERTEX PHARMACEUTICALS INC | 11,010 | $5M | 3.5% | NEW |
| 14 | IQVIQVIA HLDGS INC | 25,668 | $4M | 3.1% | NEW |
| 15 | MPLTMAPLIGHT THERAPEUTICS INC | 192,139 | $4M | 2.8% | NEW |
| 16 | ARVNARVINAS INC | 312,620 | $3M | 2.4% | NEW |
| 17 | ORKAORUKA THERAPEUTICS INC | 63,591 | $3M | 2.2% | NEW |
| 18 | UTHRUnited Therapeutics Corp. | 5,186 | $3M | 2.2% | TRIM −45% |
| 19 | TVTXTRAVERE THERAPEUTICS INC | 102,754 | $3M | 2.2% | ADD 170% |
| 20 | TRVITREVI THERAPEUTICS INC | 251,566 | $3M | 2.1% | ADD 70% |
| 21 | ANLADLAI NORTYE LTD | 414,852 | $3M | 2.1% | NEW |
| 22 | CABACABALETTA BIO INC | 1,066,239 | $3M | 2.0% | TRIM −53% |
| 23 | PFEPFIZER INC | 74,000 | $2M | 1.5% | NEW |
| 24 | AXSMAXSOME THERAPEUTICS INC. | 11,217 | $2M | 1.4% | TRIM −70% |
| 25 | ORICORIC PHARMACEUTICALS INC | 115,234 | $1M | 1.0% | TRIM −55% |
| 26 | ACRSACLARIS THERAPEUTICS INC | 366,490 | $1M | 1.0% | NEW |
| 27 | CLYMCLIMB BIO INC | 199,209 | $1M | 1.0% | NEW |
| 28 | TSHATAYSHA GENE THERAPIES INC | 258,269 | $1M | 0.8% | TRIM −74% |
| 29 | DRUGBRIGHT MINDS BIOSCIENCES INC | 13,311 | $971,304 | 0.7% | TRIM −72% |
| 30 | TNXPTONIX PHARMACEUTICALS HLDG C | 63,540 | $873,675 | 0.6% | NEW |
| 31 | CGEMCULLINAN THERAPEUTICS INC | 59,484 | $845,268 | 0.6% | NEW |
| 32 | TARAPROTARA THERAPEUTICS INC | 121,457 | $632,791 | 0.5% | TRIM −66% |
| 33 | PTNPALATIN TECHNOLOGIES INC | 35,969 | $626,580 | 0.4% | ADD 6% |
| 34 | BMEABIOMEA FUSION INC | 250,000 | $382,500 | 0.3% | HOLD |
| 35 | IPSCCENTURY THERAPEUTICS INC | 119,308 | $269,636 | 0.2% | TRIM −74% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| SMMTSUMMIT THERAPEUTICS INC | 165K | 132K | — | 197K | — | 893K | $17M |
| IMVTIMMUNOVANT INC | — | — | — | 341K | 289K | 358K | $9M |
| COGTCOGENT BIOSCIENCES INC | 911K | 775K | 963K | 361K | 366K | 225K | $9M |
| SVRASAVARA INC | 508K | 966K | 1.1M | 1.3M | 995K | 1.6M | $9M |
| URGNUROGEN PHARMA LTD | 301K | 424K | 88K | 88K | 718K | 387K | $7M |
| DFTXDEFINIUM THERAPEUTICS INC COM SHS | — | — | — | — | — | 351K | $7M |
| VIRVIR BIOTECHNOLOGY INC | — | — | — | 150K | — | 731K | $7M |
| PCVXVAXCYTE INC | — | 11K | — | — | — | 110K | $6M |
| CLDXCELLDEX THERAPEUTICS INC NEW | — | — | — | — | 88K | 180K | $6M |
| SIONSIONNA THERAPEUTICS INC | — | — | — | — | 181K | 141K | $6M |
| GMABGENMAB A/S | — | — | — | — | 29K | 197K | $5M |
| ZLABZAI LAB LTD | 404K | 295K | 135K | 201K | 197K | 276K | $5M |
| VRTXVERTEX PHARMACEUTICALS INC | — | — | — | — | — | 11K | $5M |
| IQVIQVIA HLDGS INC | — | — | — | 19K | — | 26K | $4M |
| MPLTMAPLIGHT THERAPEUTICS INC | — | — | — | — | — | 192K | $4M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
